Holen Sie sich die Stockscreener-App
24.28
4.15%
-1.05
Handel nachbörslich:
24.99
0.71
+2.92%
Lyra Therapeutics Inc Aktie (LYRA) Neueste Nachrichten
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - MSN
Northern Trust Corp Has $59,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win - insights.citeline.com
Study: LYR-210 Shows Promise in Chronic Rhinosinusitis with Nasal Polyps - Pharmacy Times
BNP Paribas Financial Markets Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Best Biotech Stocks To Watch Now – June 2nd - Defense World
Lyra Therapeutics stock hits 52-week high at $28.66 By Investing.com - Investing.com Canada
Lyra Therapeutics reports positive phase 3 trial results for CRS treatment By Investing.com - Investing.com South Africa
Applied Digital Corp, Meta Platforms, Alphabet, Lyra Therapeutics, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled - Asianet Newsable
Biotech Triumphs: Lyra, Vera, And US Gold Shine Bright - Finimize
Redemption for Lyra as second phase III rhinosinusitis trial hits goal - BioWorld MedTech
One year after massive layoffs, Lyra stock soars 400% on trial win - The Business Journals
Lyra Therapeutics (LYRA) Surges 376% on Positive Phase 3 Trial Results - GuruFocus
Microcap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data - Seeking Alpha
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Benzinga
Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win - Yahoo Finance
Lyra Therapeutics Spikes 417% as LYR-210 Redefines CRS Therapy - Wall Street Pit
LYR-210 Nasal Implant for CRS Brings Symptom Relief in Phase 3 ENLIGHTEN 2 - HCPLive
Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint - TipRanks
Lyra Therapeutics Soars on Breakthrough Nasal Implant Results - RagingBull
Lyra Therapeutics Shares Soar 603.25% to $34.67 on LYR-210 Trial Success - Trading Pedia
Transcript : Lyra Therapeutics, Inc.Special Call - marketscreener.com
Lyra Therapeutics stock hits 52-week high at $28.66 - Investing.com
Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results - TipRanks
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - marketscreener.com
Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints - marketscreener.com
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
Lyra Therapeutics Announces Positive Phase 3 Trial Results - TipRanks
LYRA Sees Promising Results in ENLIGHTEN 2 Phase 3 Trial for CRS Treatment | LYRA Stock News - GuruFocus
Lyra Therapeutics reports positive phase 3 trial results for CRS treatment - Investing.com Australia
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket - Benzinga
Lyra Therapeutics stock soars on positive Phase 3 trial results By Investing.com - Investing.com Canada
Lyra Therapeutics stock soars on positive Phase 3 trial results - Investing.com
Lyra Therapeutics Reports Positive Results from the - GlobeNewswire
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - Yahoo Finance
Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World
Lyra Therapeutics (LYRA) Trading Suspended Awaiting News Update - GuruFocus
Lyra Therapeutics (LYRA) Trading Suspended Awaiting News Update | LYRA Stock News - GuruFocus
Upcoming Stock Splits This Week (May 27 to May 30) – Stay Invested - The Globe and Mail
Chronic Rhinosinusitis Market Size, Trends, Share & Growth - openPR.com
Reviewing Silexion Therapeutics (NASDAQ:SLXN) & BioNTech (NASDAQ:BNTX) - Defense World
Petri Dish: Thermo Fisher’s new partner; Waters buys California company - The Business Journals
Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
US Stocks Likely To Open Lower After S&P 500's Six-Day Streak: 'Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,' Says ExpertASP Isotopes (NASDAQ:ASPI) - Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Lyra Therapeutics Announces Reverse Stock Split Decision - TipRanks
Lyra Therapeutics Reports Q1 2025 Financial Results - TipRanks
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates - MSN
JPMorgan Chase & Co. Has $32,000 Stake in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
JPMorgan Chase & Co. Has $40,000 Stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) - Defense World
Lyra Therapeutics to Present 52-Week Extension Stage Results for Enlighten 1 Phase 3 Study for Lyr-210 for the Treatment of Chronic Rhinosinusitis At Cosm 2025 - marketscreener.com
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Lyra Therapeutics Reports Positive Safety and Efficacy Results for LYR-210 in Phase 3 Extension Study for Chronic Rhinosinusitis - Nasdaq
Lyra Therapeutics to Present 52-week Extension Stage - GlobeNewswire
Lyra Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewswire Inc.
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - Stock Titan
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):